STEAP1: a promising target in prostate cancer therapy

Abstract

The unmet therapeutic need in prostate cancer (PCa), a disease that remains largely incurable after metastasis, underscores the urgency for new treatments. STEAP1 (six transmembrane epithelial antigen of prostate 1) is a cell surface protein highly expressed in >85% prostate tumors but shows little to no presence in normal tissues, making it a promising candidate for targeted therapy. Here, we summarize and discuss recent findings that underscore the promising role of STEAP1 in PCa therapy.

Keywords: CAR-T cell; STEAP1; T cell engagers; antibody drug conjugates; immunotherapy; metastatic castration-resistant prostate cancer.